文献速递肝病消化道肿瘤与早癌

CXCR2抑制使NASH-HCC对免疫治疗敏感

CXCR2 inhibition enables NASH-HCC immunotherapy.
PubMed 文献 · Gut · 2022-04-27

该研究在人类及小鼠NASH-HCC中观察到表达CXCR2的中性粒细胞富集,在缺乏ICI应答的小鼠模型中,CXCR2拮抗剂联合抗PD1可抑制肿瘤负荷并延长生存,机制涉及肿瘤内XCR1+树突状细胞活化、CD8+ T细胞增多及肿瘤相关中性粒细胞由促瘤向抗瘤表型重编程。

要点

  • NASH-HCC中表达CXCR2的中性粒细胞高度富集。
  • CXCR2拮抗剂联合抗PD1抑制肿瘤负荷并延长生存。
  • 联合治疗使肿瘤相关中性粒细胞由促瘤向抗瘤表型重编程。

核心结论

  • CXCR2抑制诱导肿瘤免疫微环境重编程,从而促进NASH-HCC对ICI的应答。

研究设计与样本

  • 在人类HCC及小鼠HCC模型中表征中性粒细胞浸润。
  • 在小鼠NASH-HCC模型中实施抗PD1和/或CXCR2抑制剂的晚期干预。
  • 采用成像质谱流式、RNA-seq和流式细胞术表征肿瘤免疫微环境。

主要发现

  • 表达CXCR2的中性粒细胞在人类NASH-HCC中高度富集。
  • 在缺乏ICI应答的NASH-HCC模型中,CXCR2拮抗剂联合抗PD1抑制肿瘤负荷并延长生存。
  • 联合治疗增加肿瘤内XCR1+树突状细胞活化及CD8+ T细胞数量,该效应在髓系细胞募集遗传受损、XCL1中和或CD8+ T细胞清除后消失。
  • 联合治疗伴随肿瘤相关中性粒细胞增加,其由促瘤表型转变为抗瘤祖细胞样中性粒细胞表型。
  • 重编程的肿瘤相关中性粒细胞与CD8+ T细胞直接接触形成富含颗粒酶B的簇,循环中未观察到中性粒细胞重编程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint inhibition (ICI). We hypothesised that targeting neutrophils using a CXCR2 small molecule inhibitor may sensitise NASH-HCC to ICI therapy. DESIGN: Neutrophil infiltration was characterised in human HCC and mouse models of HCC. Late-stage intervention with anti-PD1 and/or a CXCR2 inhibitor was performed in murine models of NASH-HCC. The tumour immune microenvironment was characterised by imaging mass cytometry, RNA-seq and flow cytometry. RESULTS: Neutrophils expressing CXCR2, a receptor crucial to neutrophil recruitment in acute-injury, are highly represented in human NASH-HCC. In models of NASH-HCC lacking response to ICI, the combination of a CXCR2 antagonist with anti-PD1 suppressed tumour burden and extended survival. Combination therapy increased intratumoural XCR1+ dendritic cell activation and CD8+ T cell numbers which are associated with anti-tumoural immunity, this was confirmed by loss of therapeutic effect on genetic impairment of myeloid cell recruitment, neutralisation of the XCR1-ligand XCL1 or depletion of CD8+ T cells. Therapeutic benefit was accompanied by an unexpected increase in tumour-associated neutrophils (TANs) which switched from a protumour to anti-tumour progenitor-like neutrophil phenotype. Reprogrammed TANs were found in direct contact with CD8+ T cells in clusters that were enriched for the cytotoxic anti-tumoural protease granzyme B. Neutrophil reprogramming was not observed in the circulation indicative of the combination therapy selectively influencing TANs. CONCLUSION: CXCR2-inhibition induces reprogramming of the tumour immune microenvironment that promotes ICI in NASH-HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Leslie J, Mackey JBG, Jamieson T, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022. PMID: 35477863. doi:10.1136/gutjnl-2021-326259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。